News stories about Axsome Therapeutics (NASDAQ:AXSM) have trended somewhat positive recently, according to Accern. The research firm scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Axsome Therapeutics earned a news sentiment score of 0.00 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.9103121459037 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Axsome Therapeutics Inc (AXSM) CFO Nick Pizzie Purchases 31,000 Shares (americanbankingnews.com)
- Global Complex Regional Pain Syndrome Treatment Market Study 2018- Abiogen Pharma SpA, Axsome Therapeutics … (thetricountypress.com)
- How Expensive A Stock is Relative to the Earnings Produced Per Share – Axsome Therapeutics Inc (NASDAQ: AXSM) (stocksmarketcap.com)
- Have a look on Price-Earnings Ratio->These ratio reflects investors’ assessments of those future earnings Enphase … (thestreetpoint.com)
- Relative Strength Index (RSI 14) on the Move: Axsome Therapeutics, Inc. (NASDAQ:AXSM), Capstead Mortgage … (stocksnewspoint.com)
Several research analysts have recently weighed in on AXSM shares. BTIG Research reissued a “buy” rating and set a $16.00 price objective on shares of Axsome Therapeutics in a report on Sunday, April 29th. HC Wainwright started coverage on shares of Axsome Therapeutics in a report on Thursday, June 7th. They set a “buy” rating and a $10.00 price objective for the company. Zacks Investment Research cut shares of Axsome Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, March 13th. Finally, ValuEngine raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. Axsome Therapeutics currently has a consensus rating of “Buy” and an average target price of $15.30.
Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Tuesday, May 8th. The company reported ($0.19) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.09. sell-side analysts predict that Axsome Therapeutics will post -1.08 earnings per share for the current year.
In other Axsome Therapeutics news, CFO Nick Pizzie bought 31,000 shares of Axsome Therapeutics stock in a transaction on Tuesday, June 19th. The stock was acquired at an average cost of $3.10 per share, with a total value of $96,100.00. Following the completion of the acquisition, the chief financial officer now owns 400 shares in the company, valued at $1,240. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 34.30% of the stock is currently owned by corporate insiders.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.